SUN PHARMACEUTICAL IND L vs Twilight Litaka Pharma Ltd

A side-by-side comparison of SUN PHARMACEUTICAL IND L (SUNPHARMA) and Twilight Litaka Pharma Ltd (TWILITAKA) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, SUN PHARMACEUTICAL IND L leads SUNPHARMA vs TWILITAKA on 10 of 14 metrics (1 undecided). See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

  • Valuation22
  • Profitability40
  • Growth10
  • Size & financial health31

Valuation

Even

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

40.36
P/E ratio
0.00
20.07
P/B ratio
0.00
0.84%
Dividend yield
0.00%
₹47.84
EPS
₹-56.91

Profitability

SUNPHARMA takes 4/4

How efficiently each company turns capital and sales into profit. Higher is better.

16.00%
Return on equity
0.00%
21.00%
Return on capital
-5.00%
30.00%
EBITDA margin
-28.00%
19.69%
Net margin
-440.63%

Growth

SUNPHARMA takes 1/2

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

10.03%
Revenue CAGR (3Y)
-63.48%
10.57%
Profit CAGR (3Y) even

Size & financial health

SUNPHARMA takes 3/4

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹4.63L Cr
Market cap
₹0 Cr
₹58,462 Cr
Revenue
₹32 Cr
₹11,509 Cr
Net profit
₹-141 Cr
0.61
Debt / equity
0.00
SUN PHARMACEUTICAL IND L
  • + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 34.1%"]
  • ["The company has delivered a poor sales growth of 11.8% over past five years."]
Twilight Litaka Pharma Ltd
  • ["Company has low interest coverage ratio.", "The company has delivered a poor sales growth of -38.9% over past five years.", "Company has high debtors of 2,342 days.", "Working capital days have increased from 467 days to 1,003 days"]
SUN PHARMACEUTICAL IND L full analysis Twilight Litaka Pharma Ltd full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.